Lack of effects of astemizole on vestibular ocular reflex, motion sickness, and cognitive performance in man

R. L. Kohl, J. L. Homick, Nitza Cintron, D. S. Calkins

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Astemizole was orally administered to 20 subjects in a randomized, double-blind design to assess the efficacy of this peripherally active antihistamine as an antimotion sickness drug possessing no central side-effects. Measures of vestibular ocular reflex (VOR) were made to evaluate the agent as a selective vestibular depressant. Following 1 week of orally administered astemizole (30 mg daily), a Staircase Profile Test, a VOR test, and a variety of tests of cognitive performance were administered. These tests revealed no statistically significant effects of astemizole. This leads us to conclude that, although the drug probably reaches the peripheral vestibular apparatus in man by crossing the blood-vestibular barrier, a selective peripheral antihistamine (H1) action is inadequate to control motion sickness induced through cross-coupled accelerative semicircular canal stimulation in a rotating chair.

Original languageEnglish (US)
Pages (from-to)1171-1174
Number of pages4
JournalAviation Space and Environmental Medicine
Volume58
Issue number12
StatePublished - 1987
Externally publishedYes

Fingerprint

Astemizole
Motion Sickness
Canals
Motion control
Reflex
Blood
Histamine Antagonists
Labyrinth Vestibule
Semicircular Canals
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pollution
  • Medicine(all)
  • Public Health, Environmental and Occupational Health

Cite this

Lack of effects of astemizole on vestibular ocular reflex, motion sickness, and cognitive performance in man. / Kohl, R. L.; Homick, J. L.; Cintron, Nitza; Calkins, D. S.

In: Aviation Space and Environmental Medicine, Vol. 58, No. 12, 1987, p. 1171-1174.

Research output: Contribution to journalArticle

@article{93481846e28644b490074d58778bc84b,
title = "Lack of effects of astemizole on vestibular ocular reflex, motion sickness, and cognitive performance in man",
abstract = "Astemizole was orally administered to 20 subjects in a randomized, double-blind design to assess the efficacy of this peripherally active antihistamine as an antimotion sickness drug possessing no central side-effects. Measures of vestibular ocular reflex (VOR) were made to evaluate the agent as a selective vestibular depressant. Following 1 week of orally administered astemizole (30 mg daily), a Staircase Profile Test, a VOR test, and a variety of tests of cognitive performance were administered. These tests revealed no statistically significant effects of astemizole. This leads us to conclude that, although the drug probably reaches the peripheral vestibular apparatus in man by crossing the blood-vestibular barrier, a selective peripheral antihistamine (H1) action is inadequate to control motion sickness induced through cross-coupled accelerative semicircular canal stimulation in a rotating chair.",
author = "Kohl, {R. L.} and Homick, {J. L.} and Nitza Cintron and Calkins, {D. S.}",
year = "1987",
language = "English (US)",
volume = "58",
pages = "1171--1174",
journal = "Aerospace medicine and human performance",
issn = "2375-6314",
publisher = "Aerospace Medical Association",
number = "12",

}

TY - JOUR

T1 - Lack of effects of astemizole on vestibular ocular reflex, motion sickness, and cognitive performance in man

AU - Kohl, R. L.

AU - Homick, J. L.

AU - Cintron, Nitza

AU - Calkins, D. S.

PY - 1987

Y1 - 1987

N2 - Astemizole was orally administered to 20 subjects in a randomized, double-blind design to assess the efficacy of this peripherally active antihistamine as an antimotion sickness drug possessing no central side-effects. Measures of vestibular ocular reflex (VOR) were made to evaluate the agent as a selective vestibular depressant. Following 1 week of orally administered astemizole (30 mg daily), a Staircase Profile Test, a VOR test, and a variety of tests of cognitive performance were administered. These tests revealed no statistically significant effects of astemizole. This leads us to conclude that, although the drug probably reaches the peripheral vestibular apparatus in man by crossing the blood-vestibular barrier, a selective peripheral antihistamine (H1) action is inadequate to control motion sickness induced through cross-coupled accelerative semicircular canal stimulation in a rotating chair.

AB - Astemizole was orally administered to 20 subjects in a randomized, double-blind design to assess the efficacy of this peripherally active antihistamine as an antimotion sickness drug possessing no central side-effects. Measures of vestibular ocular reflex (VOR) were made to evaluate the agent as a selective vestibular depressant. Following 1 week of orally administered astemizole (30 mg daily), a Staircase Profile Test, a VOR test, and a variety of tests of cognitive performance were administered. These tests revealed no statistically significant effects of astemizole. This leads us to conclude that, although the drug probably reaches the peripheral vestibular apparatus in man by crossing the blood-vestibular barrier, a selective peripheral antihistamine (H1) action is inadequate to control motion sickness induced through cross-coupled accelerative semicircular canal stimulation in a rotating chair.

UR - http://www.scopus.com/inward/record.url?scp=0023502013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023502013&partnerID=8YFLogxK

M3 - Article

VL - 58

SP - 1171

EP - 1174

JO - Aerospace medicine and human performance

JF - Aerospace medicine and human performance

SN - 2375-6314

IS - 12

ER -